A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract

Francisco M Marty, Roy F Chemaly, Kathleen M Mullane, Dong-Gun Lee, Hans H Hirsch, Catherine B Small, Anne Bergeron, Shmuel Shoham, Per Ljungman, Alpana Waghmare, Elodie Blanchard, Yae-Jean Kim, Matt McKevitt, Danielle P Porter, Robert Jordan, Ying Guo, Polina German, Michael Boeckh, Timothy R Watkins, Jason W Chien, Sanjeet S Dadwal, Francisco M Marty, Roy F Chemaly, Kathleen M Mullane, Dong-Gun Lee, Hans H Hirsch, Catherine B Small, Anne Bergeron, Shmuel Shoham, Per Ljungman, Alpana Waghmare, Elodie Blanchard, Yae-Jean Kim, Matt McKevitt, Danielle P Porter, Robert Jordan, Ying Guo, Polina German, Michael Boeckh, Timothy R Watkins, Jason W Chien, Sanjeet S Dadwal

Abstract

Background: Presatovir significantly reduced nasal viral load, signs, and symptoms of respiratory syncytial virus (RSV) infection in a human challenge study. We evaluated presatovir in hematopoietic-cell transplant (HCT) recipients with RSV lower respiratory tract infection (LRTI).

Methods: Patients with confirmed RSV in upper and lower respiratory tract and new chest X-ray abnormalities were randomized (1:1), stratified by supplemental oxygen and ribavirin use, to receive oral presatovir 200 mg or placebo every 4 days for 5 doses. The primary endpoint was time-weighted average change in nasal RSV viral load through day 9. Secondary endpoints included supplemental oxygen-free days, incident respiratory failure requiring mechanical ventilation, and all-cause mortality.

Results: From January 31, 2015, to March 20, 2017, 60 patients from 17 centers were randomized (31 presatovir, 29 placebo); 59 received study treatment (50 allogeneic, 9 autologous HCT). In the efficacy population (29 presatovir, 28 placebo), presatovir treatment did not significantly reduce time-weighted average change in viral load (-1.12 vs -1.09 log10 copies/mL; treatment difference -0.02 log10 copies/mL, 95% confidence interval: -.62, .57; P = .94), median supplemental oxygen-free days (26 vs 28 days, P = .84), incident respiratory failure (10.3 vs 10.7%, P = .98), or all-cause mortality (0 vs 7.1%, P = .19) versus placebo. Adverse events were similar between arms (presatovir 80%, placebo 79%). Resistance-associated substitutions in RSV fusion protein emerged in 6/29 presatovir-treated patients.

Conclusions: Presatovir treatment was well tolerated in HCT patients with RSV LRTI but did not improve virologic or clinical outcomes versus placebo.

Clinical trials registration: www.clinicaltrials.gov, NCT02254421; EudraCT, #2014-002475-29.

Keywords: Presatovir; hematopoietic cell transplant; lower respiratory tract infection; respiratory syncytial virus.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Patient disposition from screening through analysis. The adverse events leading to discontinuation of study drug were acute liver injury with cholestasis in 1 presatovir-treated patient; and sepsis and respiratory failure, bacterial infection and pancytopenia, and leukopenia in 1 placebo-treated patient each. aIncludes the patient who withdrew consent without completing study treatment. bIncludes the patient who died before completing study treatment. c1 patient in each group did not have detectable RSV RNA on day 1. Abbreviations: LRT, lower respiratory tract; RSV, respiratory syncytial virus.
Figure 2.
Figure 2.
Presatovir treatment did not significantly reduce respiratory syncytial virus (RSV) RNA relative to placebo. Panel (A) shows median nasal RSV RNA and panel (B) shows median change from baseline in nasal RSV RNA at each study visit in patients treated with presatovir (solid circles and lines) vs placebo (open circles, dashed lines) in the efficacy population. Error bars represent the interquartile range. Numbers below the graph are n at each time point.

References

    1. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371–84.
    1. Kim YJ, Guthrie KA, Waghmare A, et al. . Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis 2014; 209:1195–204.
    1. Waghmare A, Xie H, Kimball L, et al. . Supplemental oxygen-free days in hematopoietic cell transplant recipients with respiratory syncytial virus. J Infect Dis 2017; 216:1235–44.
    1. Shah DP, Ghantoji SS, Shah JN, et al. . Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013; 68:1872–80.
    1. Whimbey E, Champlin RE, Couch RB, et al. . Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996; 22:778–82.
    1. Whimbey E, Champlin RE, Englund JA, et al. . Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16:393–9.
    1. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117:2755–63.
    1. VIRAZOLE®(Ribavirin for Inhalation Solution, USP). Full Prescribing Information. Bridgewater, NJ, USA: Valeant Pharmaceuticals North America LLC, 2016.
    1. Chemaly RF, Aitken SL, Wolfe CR, Jain R, Boeckh MJ. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis 2016; 18:634–6.
    1. Boeckh M, Englund J, Li Y, et al. ; NIAID Collaborative Antiviral Study Group Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44:245–9.
    1. Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood 2016; 127:2682–92.
    1. SYNAGIS® (palivizumab) injection, for intramuscular use. Full prescribing information. Gaithersburg, MD, USA: MedImmune, LLC, May 2017. Available from . Accessed February 27, 2018.
    1. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:415–20.
    1. de Fontbrune FS, Robin M, Porcher R, et al. . Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45:1019–24.
    1. Mackman RL, Sangi M, Sperandio D, et al. . Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem 2015; 58:1630–43.
    1. DeVincenzo JP, Whitley RJ, Mackman RL, et al. . Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014; 371:711–22.
    1. German P, Xin Y, Chien JW, et al. . Phase 1 first-in-human, single- and multiple-ascending dose, and food effect studies to assess the safety, tolerability, and pharmacokinetics of presatovir for the treatment of respiratory syncytial virus infection. J Clin Pharmacol 2018; 58:1025–34.
    1. Xin Y, Weng W, Murray BP, et al. . The drug-drug interaction profile of presatovir. J Clin Pharmacol 2018; 58:771–80.
    1. Frazee BW, Rodriguez-Hoces de la Guardia A, Alter H, et al. . Accuracy and discomfort of different types of intranasal specimen collection methods for molecular influenza testing in emergency department patients. Ann Emerg Med 2018; 71:509–17 e1.
    1. Smieja M, Castriciano S, Carruthers S, et al. . Development and evaluation of a flocked nasal midturbinate swab for self-collection in respiratory virus infection diagnostic testing. J Clin Microbiol 2010; 48:3340–2.
    1. Dmitrienko A, Offen WW, Westfall PH. Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Stat Med 2003; 22:2387–400.
    1. DeVincenzo JP, McClure MW, Symons JA, et al. . Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 2015; 373:2048–58.
    1. DeVincenzo J, Tait D, Oluwayi O, et al. . Safety and efficacy of oral RV521 in a human respiratory syncytial virus (RSV) phase 2a challenge study. Am J Respir Crit Care Med 2018; 197:A7715.
    1. Chemaly RF, Dadwal SS, Bergeron A, et al. . A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients. Clin Infect Dis 2019. doi:10.1093/cid/ciz1166
    1. Gottlieb J, Torres F, Haddad T, et al. . A phase 2b, randomized controlled trial of presatovir, an oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in lung transplant (LT) recipients. J Heart Lung Transplant 2018; 37:S155.
    1. Hanfelt-Goade D, Maimon N, Nimer A, et al. . A phase 2b, randomized, double-blind, placebo-controlled trial of presatovir (GS-5806), a novel oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults. Am J Respir Crit Care Med 2018;197: A4457.
    1. Brookes DW, Coates M, Allen H, et al. . Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium. Br J Pharmacol 2018; 175:2520–34.
    1. Welliver TP, Garofalo RP, Hosakote Y, et al. . Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007; 195:1126–36.
    1. Chemaly RF, Ghosh S, Bodey GP, et al. . Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006; 85:278–87.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться